SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

infliximab-abda

TEVA·Teva Pharmaceutical Industries Ltd
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market (FDA-approved since April 2017). Teva will take over US commercialization in Q3 2027.
Why 4/10
The next hard catalyst is the Q3 2027 transfer of US commercialization rights to Teva, roughly 10 months away. Since infliximab-abda is already FDA-approved and marketed, there is no binary regulatory decision pending. For a company of Teva's size (~$17B revenue), this single biosimilar represents a modest piece of the portfolio, capping the impact score.
Actionable Insight NEUTRAL

Watch for the closing of the Teva-Samsung Bioepis deal (expected by year-end 2026) and the Q3 2027 commercialization transfer of infliximab-abda. The key question is whether Teva can grow Renflexis market share in a crowded infliximab biosimilar field against Celltrion's Inflectra, Amgen's Avsola, and Pfizer's Ixifi.

Price Chart

Loading chart...

Executive Summary

Infliximab-abda (brand name Renflexis) is an FDA-approved biosimilar of Remicade (infliximab), an anti-TNF biologic for autoimmune diseases. Developed by Samsung Bioepis and originally commercialized in the US by Merck, it was approved in April 2017. On November 3, 2026, Teva Pharmaceutical Industries announced an agreement to acquire US commercialization rights for infliximab-abda (effective Q3 2027) and ETICOVO (upon deal close), in a partnership valued at up to $420 million. The deal is part of a broader strategic collaboration between Teva and Samsung Bioepis covering up to six biosimilar candidates. For Teva, a ~$17B revenue diversified pharma company, infliximab-abda is one of many products and represents a modest addition to its biosimilars portfolio in a competitive market with three other FDA-approved infliximab biosimilars.

How It Works

Infliximab-abda is a biosimilar (a near-identical copy) of Remicade (infliximab), a biologic drug that blocks tumor necrosis factor-alpha (TNF-alpha), a protein that causes inflammation in the body. By neutralizing TNF-alpha, it reduces inflammation and symptoms in autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is administered as an intravenous infusion.

Trial Status

FDA-approved since April 2017. Renflexis has been commercially available in the US since July 2017, originally commercialized by Merck. Teva will assume US commercialization rights in Q3 2027 under a new agreement with Samsung Bioepis.

The Two-Sided Case

▲ Bull Case4
infliximab-abda (Renflexis) has been FDA-approved since 2017 with a proven track record of clinical efficacy and supply reliability, removing regulatory risk.
Teva gains US commercialization rights as part of a broader strategic partnership with Samsung Bioepis covering up to six biosimilar candidates, signaling long-term pipeline depth.
The biosimilar market for TNF inhibitors continues to grow as biologics lose patent protection and payers push for lower-cost alternatives.
Teva's existing commercial infrastructure and generics powerhouse positioning should support efficient market penetration.
▼ Bear Case4
The infliximab biosimilar market in the US already has four approved competitors (Inflectra/Celltrion, Renflexis/Samsung Bioepis, Ixifi/Pfizer, Avsola/Amgen), making it a crowded, price-competitive space.
Teva does not take over commercialization until Q3 2027, nearly a year away, giving incumbents time to solidify market positions.
Teva is a large diversified company (~$17B annual revenue), so this single biosimilar will have a modest impact on overall financials even if successful.
The deal requires upfront and milestone payments of up to $420 million, adding cost before revenue ramps.

Upcoming Catalysts

  • Closing of Teva-Samsung Bioepis deal (expected by year-end 2026)
  • Transfer of US commercialization rights for infliximab-abda to Teva (Q3 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Teva Pharmaceutical Industries Ltd Press Release TEVA ·Originating report

Sources · 8

Hover a chip for the title
1 crweworld.com2 en.sedaily.com3 stocktitan.net4 accessdata.fda.gov5 samsungbioepis.com6 regulatoryimpact.com7 tevapharm.com8 via.ritzau.dk